LIMN Stock Summary and Trading Ideas (Liminatus Pharma - Class A | NASDAQ:LIMN)

Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.

What symbol and exchange does Liminatus Pharma - Class A shares trade?

Liminatus Pharma - Class A trades on the NASDAQ stock market under the symbol LIMN.

What is Liminatus Pharma - Class A stock price doing today?

As of December 19, 2025, LIMN stock price declined to $0.79 with 53,594 million shares trading.

What is Liminatus Pharma - Class A's Beta?

LIMN has a beta of 4.78, meaning it tends to be more sensitive to market movements. LIMN has a correlation of 0.05 to the broad based SPY ETF.

How much is Liminatus Pharma - Class A worth?

LIMN has a market cap of $21.38 million. This is considered a Sub-Micro Cap stock.

What are the top ETFs holding Liminatus Pharma - Class A?

The top ETF exchange traded funds that LIMN belongs to (by Net Assets): VXF.

What are the support and resistance levels for Liminatus Pharma - Class A (LIMN)?

LIMN support price is $.72 and resistance is $.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LIMN shares will trade within this expected range on the day.